Yitao Tang

Yitao Tang

Auto-generated profile, based on publicly available information

Yitao Tang

Department of Bioinformatics and Computational Biology The University of Texas MD Anderson Cancer Center 77030 Houston TX USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
WLWei Liu
Wei Liu
JLJun Li
Jun Li
YTYitao Tang
Yitao Tang
YZYining Zhao
Yining Zhao
CLChaozhong Liu
Chaozhong Liu
HLHan Liang
Han Liang
Functional proteomics provides critical insights into cancer mechanisms, facilitating the discovery of novel biomarkers and therapeutic targets. We have developed a comprehensive cancer functional proteomics resource using reverse phase protein arrays, incorporating data from nearly 8000 patient samples from The Cancer Genome Atlas and approximately 900 samples from the Cancer Cell Line Encyclopedia. Our dataset includes a curated panel of nearly 500 high-quality antibodies, covering all major cancer hallmark pathways. To enhance the accessibility and analytic power of this resource, we introduce DrBioRight 2.0 (https://drbioright.org), an intuitive bioinformatic platform powered by state-of-the-art large language models. DrBioRight enables researchers to explore protein-centric cancer omics data, perform advanced analyses, visualize results, and engage in interactive discussions using natural language. By streamlining complex proteogenomic analyses, this tool accelerates the translation of large-scale functional proteomics data into meaningful biomedical insights.

8 April 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
YXYaru Xu
Yaru Xu
YYYuqiu Yang
Yuqiu Yang
ZWZhaoning Wang
Zhaoning Wang
MSMartin Sjöström
Martin Sjöström
YJYuyin Jiang
Yuyin Jiang
PMPing Mu
Ping Mu
Cancer cells exhibit phenotypical plasticity and epigenetic reprogramming that allows them to evade lineage-dependent targeted treatments by adopting lineage plasticity. The underlying mechanisms by which cancer cells exploit the epigenetic regulatory machinery to acquire lineage plasticity and therapy resistance remain poorly understood. We identified zinc finger protein 397 (ZNF397) as a bona fide coactivator of the androgen receptor (AR), essential for the transcriptional program governing AR-driven luminal lineage. ZNF397 deficiency facilitates the transition of cancer cell from an AR-driven luminal lineage to a ten-eleven translocation 2 (TET2)-driven lineage plastic state, ultimately promoting resistance to therapies inhibiting AR signaling. Intriguingly, our findings indicate that a TET2 inhibitor can eliminate the resistance to AR-targeted therapies in ZNF397-deficient tumors. These insights uncover a novel mechanism through which prostate cancer acquires lineage plasticity via epigenetic rewiring and offer promising implications for clinical interventions designed to overcome therapy resistance dictated by lineage plasticity. Significance: This study reveals a bifurcated role of ZNF397, and a TET2–driven epigenetic mechanism regulating tumor lineage plasticity and therapy response in prostate cancer, enhances the understanding of drug resistance, and unveils a new therapeutic strategy for overcoming androgen receptor-targeted therapy resistance.

21 February 2025 in Science Advances
Verified
Journal Article
Open access
RBRecep Bayraktar
Recep Bayraktar
YTYitao Tang
Yitao Tang
MDMihnea Dragomir
Mihnea Dragomir
CICristina Ivan
Cristina Ivan
XPXinxin Peng
Xinxin Peng
George CalinGeorge Calin
George Calin
The mutational landscape of phylogenetically ultraconserved elements (UCEs), especially those in noncoding DNAs (ncUCEs), and their functional relevance in cancers remain poorly characterized. Here, we perform a systematic analysis of whole-genome and in-house targeted UCE sequencing datasets from more than 3000 patients with cancer of 13,736 UCEs and demonstrate that ncUCE somatic alterations are common. Using a multiplexed CRISPR knockout screen in colorectal cancer cells, we show that the loss of several altered ncUCEs significantly affects cell proliferation. In-depth functional studies in vitro and in vivo further reveal that specific ncUCEs can be enhancers of tumor suppressors (such as ARID1B) and silencers of oncogenic proteins (such as RPS13). Moreover, several miRNAs located in ncUCEs are recurrently mutated. Mutations in miR-142 locus can affect the Drosha-mediated processing of precursor miRNAs, resulting in the down-regulation of the mature transcript. These results provide systematic evidence that specific ncUCEs play diverse regulatory roles in cancer.

11 May 2026 in Nature Communications
Verified
Journal Article
Open access
CLChing-Fei Li
Ching-Fei Li
YWYongkun Wei
Yongkun Wei
HLHeng-Huan Lee
Heng-Huan Lee
WCWei-Chao Chang
Wei-Chao Chang
YXYun Xiong
Yun Xiong
MHMien-Chie Hung
Mien-Chie Hung
Adenosine deaminase acting on RNA 1 (ADAR1) contributes to immunotherapy resistance by suppressing interferon signaling. Therapeutic targeting of ADAR1 has not been achieved to date in clinical settings. Here, we discover all-trans retinoic acid (ATRA) promotes ADAR1 protein degradation in cancer. In addition, ATRA induces PD-L1 and combination of ATRA and PD-1 blockade reprograms tumor microenvironments to unleash antitumor immunity, thereby impeding tumor growth. Mechanistically, we identify USP7 as a key regulator for ADAR1 protein stability. ATRA disrupts USP7-ADAR1 interaction and promotes ADAR1 ubiquitination and degradation. ATRA leads to ADAR1 retinoylation, which results in disruption of USP7-ADAR1 complex. Our clinical data shows a positive correlation between USP7 and ADAR1 in various types of cancer. Overall, this study sheds light on control of ADAR1 protein turnover and proposes a mechanism-driven combination therapy using ATRA and PD-1/PD-L1 blockade to convert immunologically "cold" into "hot" tumors, holding potential for clinical translation.

29 July 2024
Verified
Other
Open access
YXYaru Xu
Yaru Xu
YYYuqiu Yang
Yuqiu Yang
ZWZhaoning Wang
Zhaoning Wang
MSMartin Sjöström
Martin Sjöström
YJYuyin Jiang
Yuyin Jiang
PMPing Mu
Ping Mu
Table S3. Significantly Enriched or Depleted Signaling Pathways in GSEA Analysis

29 July 2024
Verified
Other
Open access
YXYaru Xu
Yaru Xu
YYYuqiu Yang
Yuqiu Yang
ZWZhaoning Wang
Zhaoning Wang
MSMartin Sjöström
Martin Sjöström
YJYuyin Jiang
Yuyin Jiang
PMPing Mu
Ping Mu
Table S6 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer